Ticker Symbol: KA

Kineta Inc

Exchange: NASDAQ Country: US Currency: USD Asset Type: Common Stock CIK:0001445283

Company Profile

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform is designed to enable the Company to rapidly screen for potential disease-modifying therapies by overcoming toxicity of misfolded proteins in neurogenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi- system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease.

Sector: Manufacturing

Industry: Pharmaceutical Preparation Manufacturing

Standard Industrial Classification Code (SIC code): 2834

Address: 80 Guest St Fl 5

Website: www.proteostasis.com

CEO: Meenu Chhabra

Tags: N/A

Pricing

Last Updated: October 3, 2023 03:00 PM EST

Previous Close: $3.95

Change: -$0.54 ( -12.03%)

Days Range: $3.75 - $5.39

Beta: -2.50

52wk. High: $9.00

52wk. Low: $0.28

Ytd. Change -41.32%

50 Day Moving Average: $2.84

200 Day Moving Average: $2.86

Shares Outstanding: 9769097

Valuation

Market Cap: 3.9B

PE Ratio: -

EPS (TTM): 0

Dividends

Dividend Per Share (TTM): -

Dividend Yield (TTM): 0.00%

Ex-Dividend Date: N/A